Teriparatide/Abaloparatide: Initiation
Initiate Teriparatide SQ 20 mcg daily or Abaloparatide SQ 80 mcg daily with a maximum duration of 2 years
Unlike denosumab or romosozumab, teriparatide and Abaloparatide can be self administered
Administer as a subcutaneous injection into the thigh or abdominal wall
Implement monitoring:
- Orthostatic vital signs after first dose in office
- Serum calcium after 2-3 months and consider intermittent monitoring based on risk of hypercalcemia
Note: There may also be an increase in serum uric acid and renal stones. Other common side effects include arthralgia, MSK pain, and nausea
Sources: Abaloparatide package insert, Teriparatide package insert